Strengthening Sweden’s Biologics Value Chain: Diamyd Medical Partners with NorthX Biologics
By Rebeca Varela Lores, Investment Associate
February 3, 2026
Image provided by Diamyd Medical.
Sweden continues to build momentum as a hub for advanced biologics manufacturing as Diamyd Medical deepens its long-term collaboration with Apotek Produktion & Laboratorier (APL) and enters a strategic partnership with NorthX Biologics.
The collaboration brings together Diamyd Medical’s in-house drug substance manufacturing at its Umeå facility with APL’s GMP fill-and-finish expertise and NorthX Biologics’ capabilities in validation, scale-up, and regulatory readiness. By consolidating critical competencies locally, the alliance supports controlled scale-up, reduces manufacturing risk, and strengthens Sweden’s position in the global biologics value chain as Diamyd Medical prepares for the future commercialization of retogatein (rhGAD65).
Read the full official press release from Diamyd Medical here
About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes. Its lead candidate, retogatein (rhGAD65), is an investigational antigen-specific immunotherapy designed to preserve endogenous insulin production in genetically defined patient populations. The company is advancing retogatein through late-stage clinical development and is establishing in-house biomanufacturing capabilities in Umeå, Sweden.
About NorthX Biologics
NorthX Biologics is Sweden’s national innovation hub for advanced biologics and a leading CDMO with more than 30 years of GMP experience. The company provides end-to-end services including process development, validation, and manufacturing of biologics, vaccines, cell and gene therapies, and recombinant proteins, supporting customers worldwide from development through commercialization.